Intracoronary streptokinase therapy resulted in a nearly threefold reduction in 30-day mortality compared to controls (3.7% vs 11.2%, P<0.02) in patients with acute myocardial infarction.
RCT (n=250)
randomly assigned
Yes
Does intracoronary streptokinase thrombolysis reduce 30-day mortality in patients with acute myocardial infarction?
Intracoronary streptokinase therapy resulted in a nearly threefold reduction in 30-day mortality after hospitalization for acute myocardial infarction.
Absolute Event Rate: 3.7% vs 11.2%
p-value: p=<0.02
Two hundred fifty patients were enrolled in a multicenter, community-based study of the efficacy of intracoronary streptokinase thrombolysis in acute myocardial infarction; 134 were randomly assigned to streptokinase therapy and 116 were controls. All patients underwent left ventricular angiography and coronary arteriography before the random assignment. The mean time from the onset of symptoms to hospitalization was 134 +/- 144 minutes (S.D), and the mean time to random assignment was 276 +/- 185 minutes. Coronary reperfusion was achieved in 68 per cent of the streptokinase-treated group. The overall 30-day mortality was 18 (7.2 per cent); there were five deaths in the streptokinase-treated group (3.7 per cent) and 13 in the control group (11.2 per cent, P less than 0.02). Fifteen of the 18 deaths occurred in patients with anterior infarction. Intracoronary streptokinase therapy resulted in a nearly threefold reduction in the 30-day mortality after hospitalization for acute myocardial infarction.
Kennedy et al. (1983) conducted an RCT in acute myocardial infarction (n=250). intracoronary streptokinase vs. controls was evaluated on 30-day mortality (p=<0.02). Intracoronary streptokinase therapy resulted in a nearly threefold reduction in 30-day mortality compared to controls (3.7% vs 11.2%, P<0.02) in patients with acute myocardial infarction.